What Happened?
Shares of medical technology company Teleflex (NYSE: TFX) fell 5.4% in the afternoon session after the U.S. government launched a probe into the medical device industry.
The investigation appeared to affect the broader sector, as shares of other medical device companies like Baxter and GE HealthCare also declined. While the specifics of the probe were not detailed, such government inquiries often create uncertainty for investors. The potential for new regulations, fines, or other unfavorable outcomes can lead to concerns about future profitability and sales across the industry, prompting a sell-off in related stocks.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Teleflex? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Teleflex’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 7 months ago when the stock dropped 22.9% on the news that the company reported disappointing fourth-quarter results, with revenue missing expectations by a significant margin.
On a constant currency basis, revenue increased 3.2%, but this still fell short of Wall Street's estimates. Weak demand in Interventional Urology wiped out gains in the Interventional and Surgical units. Looking ahead, the company's 2025 revenue guidance implies little to no growth, with management projecting revenue to be flat to slightly up. Overall, this was a weaker quarter, weighed down by sluggish growth, margin pressures, and a subdued outlook.
Teleflex is down 34.7% since the beginning of the year, and at $116.86 per share, it is trading 52.7% below its 52-week high of $247.32 from September 2024. Investors who bought $1,000 worth of Teleflex’s shares 5 years ago would now be looking at an investment worth $348.00.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
